Premium
The immune system and new therapies for inflammatory joint disease
Author(s) -
Oliver Susan M.
Publication year - 2003
Publication title -
musculoskeletal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.628
H-Index - 28
eISSN - 1557-0681
pISSN - 1478-2189
DOI - 10.1002/msc.38
Subject(s) - medicine , immune system , joint disease , disease , immunology , joint (building) , pathology , alternative medicine , osteoarthritis , architectural engineering , engineering
This article provides an overview of the immune system with a specific focus on the role of biologic therapies in treating the consequences of an altered immune response as seen in rheumatoid arthritis (RA). Cytokines are powerful chemical messengers that have a significant role to play in activating an inflammatory response. Two dominant cytokines have been identified as crucial in the inflammatory process that can be seen in RA – tumour necrosis factor alpha (TNFα) and interleukin‐1. The term ‘biologic’ is used to describe biologically engineered therapies that are specifically designed to prevent pro‐inflammatory cytokines inducing an inflammatory response. Research trials and now clinical practice have clearly demonstrated a significant benefit to patients receiving biologic therapies. The responsibility of the practitioner is to ensure a sound knowledge of biologic therapies, to understand the essential aspects of care and to recognize the importance of guidance documents available to support management and, ultimately, the long‐term provision of safe and effective administration of these therapies. Copyright © 2003 Whurr Publishers Ltd.